ONCBeOne MedicinesNot started yet
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
Hepatocellular Cancer · Liver Cancer · Hepatocellular Carcinoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
2 insiders sold shares within a month
Since Aug 3, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 100 (planned)
- Started
- Nov 30, 2026
- Main results expected
- Mar 31, 2028
- Fully finished
- Sep 30, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Response Assessment (ORR) by Independent Review Committee Assessment
Measured over: Up to approximately 15 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.7, since 2026-08-03, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07911683 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC